In the Oncomine, TIMER, and prognostic analyses, significantly high expression levels of CDH1/2/4/7/11/12/13/15 were observed in breast cancer compared to normal tissue samples, and these were associated with poor DMFS outcomes. Here, CDH1 is linked to breast cancer.